AVROBIO, Inc. announced the appointment of four key senior management hires to expand and strengthen its leadership team as it prepares for the next stage of growth. All four leaders will be in place in January 2019 and sit on company's executive leadership team. Three of them, Birgitte Volck, M.D., Ph.D., President of Research and Development, Erik Ostrowski, Chief Financial Officer, and Steven Avruch, General Counsel, will report to company's President and CEO, Geoff MacKay.

The fourth, Josie Yang, Ph.D., Vice President and Head of Regulatory Affairs, will report to Dr. Volck. On December 17, 2018, Katina Dorton departed her positions as Chief Financial Officer of the company and as principal financial officer and principal accounting officer of the company, effective immediately. Nerissa Kreher, M.D., departed her positions as Chief Medical Officer of the company and as an executive officer of the company, effective immediately.

Dr. Kreher will continue as a senior advisor to the company until March 31, 2019, at which time her employment with the company will end. On December 18, 2018, the company announced the appointment of Erik Ostrowski as Chief Financial Officer of the company, effective on January 2, 2019. Mr. Ostrowski was also appointed as the company's principal financial officer and principal accounting officer on December 17, 2018, effective January 2, 2019.

Mr. Ostrowski joins the Company from Summit Therapeutics plc, where he was Chief Financial Officer from June 2014 to December 2018. Prior to that, he served as Vice President of Finance at Organogenesis Inc. Dr. Birgitte Volck is the former Senior Vice President and Head of R&D, Rare Disease at GSK in the UK. Prior to GSK, Birgitte was Chief Medical Officer and SVP, Head of Development at Swedish Orphan Biovitrum.

Steven Avruch, company's General Counsel, was Chief Corporation Counsel and Assistant Secretary (VP) at Biogen Inc., and prior to that worked at Biogen as an Associate General Counsel. Dr. Josie Yang, AVROBIO's Head of Regulatory Affairs, has over 25 years of experience in biomedical research in the U.S. Food and Drug Administration, and in bio-pharmaceutical industries including in regulatory affairs across all stages of drug development with biologics and small molecules in oncology, anti-inflammatory, gastroenterology and neurology therapeutic areas. Josie held leadership positions as VP and Head of Global Regulatory Strategy at PTC Therapeutics.